Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $3.3 million.

  • Apellis Pharmaceuticals' Other Non-Current Liabilities fell 6686.34% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 6686.34%. This contributed to the annual value of $8.0 million for FY2024, which is 24480.97% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Other Non-Current Liabilities of $3.3 million as of Q3 2025, which was down 6686.34% from $2.1 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $345.2 million during Q4 2021, with a 5-year trough of $347000.0 in Q1 2023.
  • For the 5-year period, Apellis Pharmaceuticals' Other Non-Current Liabilities averaged around $67.3 million, with its median value being $2.5 million (2023).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 9955.05% in 2022, then soared by 93900.63% in 2024.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Other Non-Current Liabilities stood at $345.2 million in 2021, then tumbled by 99.44% to $1.9 million in 2022, then rose by 19.3% to $2.3 million in 2023, then soared by 244.81% to $8.0 million in 2024, then tumbled by 59.14% to $3.3 million in 2025.
  • Its Other Non-Current Liabilities was $3.3 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.1 million in Q1 2025.